Targeting TAG-72 in cutaneous T cell lymphoma
Details
Publication Year 2024-09-15,Volume 10,Issue #17,Page e36298
Journal Title
Heliyon
Publication Type
Research article
Abstract
PURPOSE: Current monoclonal antibody-based treatment approaches for cutaneous T cell lymphoma (CTCL) rely heavily on the ability to identify a tumor specific target that is essentially absent on normal cells. Herein, we propose tumor associated glycoprotein-72 (TAG-72) as one such target. TAG-72 is a mucin-associated, truncated O-glycan that has been identified as a chimeric antigen receptor (CAR)-T cell target in solid tumor indications. To date, TAG-72 targeting has not been considered in the setting of hematological malignancies. EXPERIMENTAL DESIGN: CD3(+) cells from patients with CTCL were analyzed for TAG-72 expression by flow cytometry. Immunohistochemistry was used to assess TAG-72 expression in CTCL patient skin lesions and a TAG-72 ELISA was employed to assess soluble TAG-72 (CA 72-4) in patient plasma. TAG-72 CAR transduction was performed on healthy donor (HD) and CTCL T cells and characterized by flow cytometry. In vitro CAR-T cell function was assessed by flow cytometry and xCELLigence® using patient peripheral blood mononuclear cells and proof-of-concept ovarian cancer cell lines. In vivo CAR-T cell function was assessed in a proof-of-concept, TAG-72(+) ovarian cancer xenograft mouse model. RESULTS: TAG-72 expression was significantly higher on total CD3(+) T cells and CD4(+) subsets in CTCL donors across disease stages, compared to that of HDs. TAG-72 was also present in CTCL patient skin lesions, whereas CA 72-4 was detected at low levels in both CTCL patient and HD plasma with no differences between the two groups. In vitro cytotoxicity assays showed that anti-TAG-72 CAR-T cells significantly, and specifically reduced CD3(+)TAG-72(+) expressing CTCL cells, compared to culture with unedited T cells (no CAR). CTCL CAR-T cells had comparable function to HD CAR-T cells in vitro and CAR-T cells derived from CTCL patients eradicated cancer cells in vivo. CONCLUSION: This study shows the first evidence of TAG-72 as a possible target for the treatment of CTCL.
Publisher
Cell Press
Keywords
Ca 72-4; CAR-T cells; Ctcl; Tag-72
Department(s)
Clinical Haematology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-26 03:27:27
Last Modified: 2024-09-26 03:32:37

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙